Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Studio di Sicurezza e Immunogenicità di OCU500, Vettore ChAd36 che Codifica il Vaccino SARS-CoV-2 Spike, Somministrato per Via Intranasale e Inalatoria in Adulti Precedentemente Vaccinati

Uno studio di Fase 1 in aperto sulla sicurezza e immunogenicità di OCU500, vettore ChAd36 che codifica per la proteina Spike del SARS-CoV-2, un vaccino booster di nuova generazione contro il SARS-CoV-2 somministrato per via intranasale e inalatoria, in adulti precedentemente vaccinati

This phase 1 randomized, open-label, dose-escalation clinical trial evaluates the safety and immunogenicity of OCU500, a ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine, in healthy adults aged 18-64 who previously completed a primary COVID-19 vaccination series and at least one booster. The study evaluates two dose levels (1×10^10 viral particles (VP) and 5×10^10 VP) and two routes of administration (intranasal and inhaled). The trial includes 80 participants across four study arms (20 per arm). The primary objective is to evaluate the safety and reactogenicity of a single dose of OCU500 administered in previously vaccinated healthy adults.

Panoramica dello studio

Stato

Attivo, non reclutante

Condizioni

Intervento / Trattamento

Descrizione dettagliata

This phase 1 randomized, open-label, dose-escalation clinical trial evaluates the safety and immunogenicity of OCU500, a ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine, in healthy adults aged 18-64 who previously completed a primary COVID-19 vaccination series and at least one booster. The study evaluates two dose levels (1×10^10 viral particles (VP) and 5×10^10 VP) and two routes of administration (intranasal and inhaled). The trial includes 80 participants across four study arms (20 per arm). The primary objective is to evaluate the safety and reactogenicity of a single dose of OCU500 administered in previously vaccinated healthy adults. Secondary objectives include evaluating systemic anti-Spike humoral responses, nasal mucosal Immunoglobulin A (IgA) and Immunoglobulin G (IgG) responses, and immune responses toward vectors.

Tipo di studio

Interventistico

Iscrizione (Effettivo)

83

Fase

  • Fase 1

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

    • Georgia
      • Decatur, Georgia, Stati Uniti, 30030-1705
        • The Hope Clinic of Emory University
    • Maryland
      • Baltimore, Maryland, Stati Uniti, 21201-1509
        • University of Maryland, School of Medicine, Center for Vaccine Development and Global Health
    • Massachusetts
      • Boston, Massachusetts, Stati Uniti, 02115-6110
        • Brigham and Women's Hospital
    • Missouri
      • St Louis, Missouri, Stati Uniti, 63104-1015
        • Saint Louis University Center for Vaccine Development
    • Texas
      • Galveston, Texas, Stati Uniti, 77555-0435
        • University of Texas Medical Branch

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 18 anni a 64 anni (Adulto)

Accetta volontari sani

Sì

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  1. Provides written informed consent before initiation of any study procedures.

  2. Able to understand and agree to comply with planned study procedures and be available for all study visits.

  3. Non-pregnant adults, 18 through 64 years of age at the time of study product administration.

  4. Participants of childbearing potential* must agree to use or have practiced true abstinence** or use at least one acceptable primary form of contraception.***

    *These criteria apply to females who are in a heterosexual relationship and are of childbearing potential. Not of childbearing potential include post-menopausal females (defined as having a history of amenorrhea for at least one year) or a documented status as being surgically sterile (hysterectomy, bilateral oophorectomy, or tubal ligation/salpingectomy).

    **True abstinence is 100 percent of the time, no sexual intercourse (penis enters the vagina). Periodic abstinence [e.g., calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable methods.

    ***Acceptable forms of primary contraception include a monogamous relationship with a vasectomized partner who has been vasectomized for 180 days or more before the participant's study product administration, a copper intrauterine device, a levonorgestrel-releasing intrauterine device, a progestin-only oral contraceptive pill, a depot medroxyprogesterone injection, or a progestin implant. Combined hormonal contraceptives containing estrogen, including combined oral contraceptive pills, transdermal patches, and vaginal rings, are not acceptable for this trial. Must have used at least one acceptable primary form of contraception for at least 30 days before study product administration and agree to continue at least one acceptable primary form of contraception through 60 days after study product administration.

  5. Participants of childbearing potential must have a negative urine pregnancy test at screening and within 24 hours before study product administration.

  6. In general, good health.*

    *As determined by medical history and physical examination, including vital signs, to evaluate acute or ongoing chronic medical diagnoses/conditions that have been present for at least 90 days, which would affect the assessment of participant safety. Chronic medical diagnoses/ conditions should be stable for the last 30 days (i.e., no hospitalization, ER, or urgent care for the condition). This includes no change in chronic prescription medication, dose, or frequency due to deterioration of the chronic medical diagnosis or condition within the 30 days preceding the study product administration. Any prescription change that is due to a change of health care provider, insurance company, etc., or done for financial reasons, and in the same class of medication, will not be considered a deviation of this inclusion criterion. Participants may be on chronic or as-needed (prn) medications if, in the opinion of the participating site PI or appropriate sub-investigator, they pose no additional risk to participant safety or assessment of reactogenicity and immunogenicity.

  7. Receipt of a complete primary COVID-19 vaccine series and at least one booster* with last vaccination at least 16 weeks before study product administration.

    *Booster may be either homologous or heterologous to the primary vaccine series. It must be an FDA-authorized/licensed vaccine, though doses may have been received as part of a clinical trial.

  8. Clinical screening laboratory evaluations are within normal reference ranges or grade 1 with no clinical significance (NCS) per investigator discretion.*

    *(White Blood Cells [WBCs] with differential [diff], hemoglobin [Hgb], platelets [PLTs], PTT, PT, Alanine Transaminase [ALT], Aspartate Transaminase [AST], Creatinine [Cr], Alkaline Phosphatase [ALP], Total Bilirubin [T. Bili]). ALT, AST, ALP, T. Bili, and creatinine values that are below the reference range will not be exclusionary, as these values below the reference range are clinically insignificant.

  9. Must agree to have samples stored for secondary research.

  10. Must complete a Test of Understanding (ToU) before enrollment by answering 90 percent of questions correctly at least once in 3 attempts.

Exclusion Criteria:

  1. Positive SARS-CoV-2 PCR at screening.

  2. Abnormal vital signs (Grade 1 or higher).*

    *Grade 1 or higher is equivalent to: Systolic blood pressure (SBP) = 141 mmHg or = 89 mmHg Diastolic blood pressure (DBP) = 91 mmHg Heart rate (HR) is = 101 beats per minute or = 54 beats per minute Oral temperature = 38.0 degrees Celsius (100.4 degrees Fahrenheit)

  3. History of SARS-CoV-2 infection within the prior 16 weeks OR receipt of any COVID-19 vaccine within the prior 16 weeks before study product administration.

  4. Participant who is pregnant or breastfeeding or less than 12 weeks post partum at the time of study product administration.

  5. Participant has donated blood or plasma within 4 weeks prior to study product administration, or does not agree to refrain from blood or plasma donation until Day 181.

  6. Receipt of antibody or blood-derived products within 90 days before study product administration.

  7. Any significant medical or psychiatric diseases or any other condition that, in the opinion of the site PI or appropriate sub-investigator, precludes study participation.*

    *Significant self-reported or medically reported medical or psychiatric conditions include, but are not limited to drug or alcohol abuse within 6 months of enrollment, significant kidney disease, liver disease, history of hematologic malignancies, ongoing malignancy or recent diagnosis of malignancy in the last five years, excluding treated basal cell and squamous cell carcinoma of the skin, and cervical carcinoma in situ, which are allowed.

  8. Any respiratory disease, including but not limited to chronic obstructive pulmonary disease (COPD), asthma, interstitial lung disease, bronchiectasis, etc.

  9. Neurological or neurodevelopmental conditions.*

    *These conditions include: history of Bell's palsy, history of four or more migraine headaches in the past 12 months that interfered with normal daily activity or any migraine headache in the past 5 years that required emergency or inpatient medical care, epilepsy, seizures in the last 5 years, encephalopathy, focal neurologic deficits, Guillain-Barré syndrome, myelopathy, peripheral neuropathy, encephalomyelitis, transverse myelitis, stroke or transient ischemic attack, multiple sclerosis, Parkinson's disease, amyotrophic lateral sclerosis, Creutzfeldt-Jakob disease, or Alzheimer's disease.

  10. Cardiovascular disease (e.g., congestive heart failure, cardiomyopathy, ischemic heart disease), including any history of myocarditis or pericarditis, or uncontrolled cardiac arrhythmia.

  11. Any autoimmune disease, including hypothyroidism without a defined non-autoimmune cause.

  12. Any significant nasal or upper airway disease.*

    *Including, but not limited to, being prone to epistaxis, a history of inflammatory rhinitis (including allergic rhinitis) that requires daily medications, cochlear implants, head/neck radiation history, anosmia/dysosmia, conditions that require prescription or over the counter intranasal medication (intermittent use will be allowed if no use occurred for 30 days before study product administration and participant agrees to not use intranasal medication (other than steroids) for 30 days after study product administration and to not use intranasal steroids for 6 months after study product administration), and certain ear, nose and throat (ENT) conditions, including significant upper airway/nasopharyngeal disease or abnormal anatomy such as CSF leak.

  13. Has an acute illness, as determined by the site Principal Investigator or appropriate sub-investigator within 72 hours before study product administration.*

    *An acute illness which is nearly resolved with only minor residual symptoms remaining is allowable if, in the opinion of the participating site PI or appropriate sub-investigator, the residual symptoms will not interfere with the ability to assess safety parameters as required by the protocol.

  14. Has a positive test result for hepatitis B surface antigen, hepatitis C virus RNA (by reflex testing), or human immunodeficiency virus (HIV) antigen/antibody test at screening.

  15. Has any confirmed or suspected immunosuppressive or immunodeficient state, such as asplenia, recurrent severe infections, and chronic* immunosuppressant medication within the past 6 months.**

    *Chronic meaning more than 14 continuous days.

    **Ophthalmic and topical steroids are allowed, see exclusions 12 and 21 for intranasal steroids.

  16. Has received any investigational product within 60 days, or 5 half-lives, whichever is longer, before study product administration; or is planning to receive one during the study.

  17. Has a history of hypersensitivity or severe allergic reaction* to any previous licensed or unlicensed vaccine or to the candidate vaccine components.

    *e.g., anaphylaxis, generalized urticaria, angioedema, other significant reaction

  18. History of chronic idiopathic urticaria.

  19. Received or plans to receive licensed inactivated/subunit vaccine within 14 days of study product administration or live vaccine within 28 days of study product administration.

  20. Plan to receive a COVID-19 vaccine within the 180 days following study product administration.

  21. Regular use of intranasal medications, including steroids.*

    *Participant must have had no intranasal medication use for 30 days before study product administration and plans not to use intranasal medications for 30 days after study product administration for medications other than steroids, and for 6 months after study product administration for intranasal steroids (including over-the-counter fluticasone).

  22. History of smoking within three months before enrollment.*

    *Including cigarettes, smokeless and other tobacco products, e-cigarettes (to include vaping and Juuling products), marijuana, nicotine gum, and nicotine lozenges.

  23. Use of intranasal illicit drugs in the 5 years before study product administration or plans to use during the study.

  24. Planned international travel between study product administration and Day 29.

  25. Previous receipt of any adenovirus-vector vaccine by the intranasal or aerosol routes.

  26. Bleeding disorder (e.g., factor deficiency, coagulopathy, or platelet disorder), or prior history of significant bleeding or bruising following Intramuscular injections or venipuncture.

  27. Recent (within 3 months of study product administration): major surgery, >=3 days immobility, chronic infection, or head trauma that may increase thrombosis risk.*

    *Major surgery is either abdominal or vascular, or orthopedic surgery, and immobility implies bed rest.

  28. History of venous or arterial thrombosis or any known thrombophilic condition, including heparin-induced thrombocytopenia (HIT) or thrombosis.

  29. BMI >/= 40kg/m^2

  30. Current/planned systemic estrogen therapy, except stable transdermal estradiol, from 30 days pre-dose through end of study participation. Low-dose vaginal estrogen is permitted.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Prevenzione
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione sequenziale
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Arm 1

A single dose of 1×10^10 viral particles (VP) in 100 uL of OCU500 administered via inhalation on Day 1 in participants from 18 to 64 years of age. N = 20

OCU500 is a monovalent, replication-defective, chimpanzee adenovirus (ChAd36)-vectored COVID-19 vaccine that encodes a codon-optimized, stabilized prefusion form of the spike (S) protein from the Omicron XBB1.5 strain.

Sperimentale: Arm 2

A single dose of 1×10^10 viral particles (VP) in 100 uL of OCU500 administered intranasally (0.05 mL/nostril) on Day 1 in participants from 18 to 64 years of age. N = 20

OCU500 is a monovalent, replication-defective, chimpanzee adenovirus (ChAd36)-vectored COVID-19 vaccine that encodes a codon-optimized, stabilized prefusion form of the spike (S) protein from the Omicron XBB1.5 strain.

Sperimentale: Arm 3

A single dose of 5x10^10 viral particles (VP) in 100 uL of OCU500 administered via inhalation on Day 1 in participants from 18 to 64 years of age. N = 20

OCU500 is a monovalent, replication-defective, chimpanzee adenovirus (ChAd36)-vectored COVID-19 vaccine that encodes a codon-optimized, stabilized prefusion form of the spike (S) protein from the Omicron XBB1.5 strain.

Sperimentale: Arm 4

A single dose of 5x10^10 viral particles (VP) in 100 uL of OCU500 administered intranasally (0.05 mL/nostril) on Day 1 in participants from 18 to 64 years of age. N = 20

OCU500 is a monovalent, replication-defective, chimpanzee adenovirus (ChAd36)-vectored COVID-19 vaccine that encodes a codon-optimized, stabilized prefusion form of the spike (S) protein from the Omicron XBB1.5 strain.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Lasso di tempo
Presenza di eventi avversi anormali di laboratorio di sicurezza clinica (AE).
Lasso di tempo: Fino al giorno 8
Fino al giorno 8
Occorrenza di eventi avversi di speciale interesse (AESI).
Lasso di tempo: Fino a 6 mesi dopo la somministrazione del prodotto in studio
Fino a 6 mesi dopo la somministrazione del prodotto in studio
Occorrenza di eventi avversi assistiti medicalmente (MAAE).
Lasso di tempo: Fino a 6 mesi dopo la somministrazione del prodotto dello studio
Fino a 6 mesi dopo la somministrazione del prodotto dello studio
Insorgenza di nuove condizioni mediche croniche (NOCMC).
Lasso di tempo: Fino a 6 mesi dopo la somministrazione del prodotto dello studio
Fino a 6 mesi dopo la somministrazione del prodotto dello studio
Occorrenza di eventi avversi gravi (SAE).
Lasso di tempo: Fino a 6 mesi dopo la somministrazione del prodotto dello studio
Fino a 6 mesi dopo la somministrazione del prodotto dello studio
Occorrenza di eventi avversi (EA) locali sollecitati.
Lasso di tempo: Fino al Giorno 8
Fino al Giorno 8
Occorrenza di eventi avversi sistemici sollecitati (AE).
Lasso di tempo: Fino all'ottavo giorno
Fino all'ottavo giorno
Occorrenza di eventi avversi (EA) non sollecitati.
Lasso di tempo: Fino al giorno 29
Fino al giorno 29

Misure di risultato secondarie

Misura del risultato
Lasso di tempo
Livello di anticorpi anti-vettore
Lasso di tempo: Dal Giorno 1 al Giorno 91
Dal Giorno 1 al Giorno 91
Immunoglobulina A (IgA) legante mucosale nasale anti-spike del SARS-CoV-2
Lasso di tempo: Dal Giorno 1 al Giorno 181
Dal Giorno 1 al Giorno 181
Immunoglobulina G (IgG) anti-spike di SARS-CoV-2 legante la mucosa nasale
Lasso di tempo: Dal giorno 1 al giorno 181
Dal giorno 1 al giorno 181
Anticorpo di immunoglobulina A (IgA) legante il siero anti-spike del SARS-CoV-2
Lasso di tempo: Dal giorno 1 al giorno 181
Dal giorno 1 al giorno 181
Anticorpi Immunoglobulina G (IgG) leganti il siero anti-spike del SARS-CoV-2
Lasso di tempo: Dal Giorno 1 al Giorno 181
Dal Giorno 1 al Giorno 181
Anticorpi sierici neutralizzanti anti-spike del SARS-CoV-2
Lasso di tempo: Dal Giorno 1 al Giorno 181
Dal Giorno 1 al Giorno 181

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

26 maggio 2026

Completamento primario (Stimato)

29 aprile 2027

Completamento dello studio (Stimato)

1 novembre 2027

Date di iscrizione allo studio

Primo inviato

10 aprile 2026

Primo inviato che soddisfa i criteri di controllo qualità

10 aprile 2026

Primo Inserito (Effettivo)

17 aprile 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

13 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

12 novembre 2026

Ultimo verificato

14 aprile 2026

Maggiori informazioni

Termini relativi a questo studio

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

prodotto fabbricato ed esportato dagli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi